Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
Agilent (NYSE: A) announced FDA approval on March 26, 2026 for PD-L1 IHC 22C3 pharmDx, Code SK006 as a companion diagnostic to identify esophageal or gastroesophageal junction (GEJ) carcinoma patients with PD-L1 CPS ≥ 1 who may be eligible for treatment with KEYTRUDA.
This marks the eighth FDA companion diagnostic indication for 22C3. Agilent reported $6.95 billion revenue for fiscal 2025 and ~18,000 employees.
Agilent (NYSE: A) will present advances in precision oncology and digital pathology at USCAP 2026, March 21-26 in San Antonio.
Highlights include a new PD-L1 indication for epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), expanded biomarker testing, and integrated end-to-end digital pathology workflows built around the Dako Omnis family.
TORM plc (NASDAQ: TRMD / TRMD A) increased its share capital by 106,468 A-shares following exercise of Restricted Share Units (RSUs), corresponding to a nominal value of USD 1,064.68. A total of 34,880 shares were subscribed at DKK 131.80 and 71,588 at DKK 148.70.
The new ordinary A-shares carry voting and dividend rights as of issuance, are negotiable instruments, and are expected to be listed on Nasdaq Copenhagen as soon as possible. Transfer restrictions may apply in some jurisdictions, including U.S. securities law. After the increase, share capital totals USD 1,019,306.41 divided into 101,930,641 A-shares.
Agilent (NYSE: A) launched Agilent Advanced Therapeutics, a unified CDMO solution integrating BIOVECTRA (Canada) and Nucleic Acid Solutions (Colorado) to provide end-to-end development and manufacturing across discovery, process development, and clinical- and commercial-scale production.
The CDMO portfolio includes oligonucleotides, microbial fermentation, complex and synthetic chemistry, bioreagents, highly potent APIs, and cell line development, intended to streamline customer access to scalable, customizable manufacturing under a single partner.
Agilent (NYSE: A) has agreed to acquire Biocare Medical for $950 million in an all-cash transaction, adding a complementary portfolio of IHC, ISH and FISH antibodies, reagents and instruments.
Biocare generated over $90 million revenue in 2025, posted annual double-digit revenue and profit growth since 2021, and the deal is expected to be accretive to Agilent’s top-line growth, margin profile and non-instrument revenue mix in Year 1, with EPS accretion ~12 months after close. Closing is subject to regulatory approvals and expected by Agilent’s Q4 FY2026.
Agilent (NYSE: A) reported Q1 FY2026 revenue of $1.80 billion, up 7.0% reported and 4.4% core year-over-year, with GAAP EPS of $1.07 and non-GAAP EPS of $1.36. The company raised FY26 revenue guidance to $7.3–$7.5 billion and increased non-GAAP EPS range to $5.90–$6.04.
Segments: LDG revenue $679M (16.0% margin), ACG $758M (31.6% margin), AMG $361M (25.8% margin). Q2 revenue guide is $1.79–$1.82 billion; Q2 non-GAAP EPS $1.39–$1.42. Management cited weather headwinds but reaffirmed core growth and margin expansion.
Agilent (NYSE: A) will participate in TD Cowen’s 46th Annual Health Care Conference with a fireside chat featuring CFO Adam Elinoff and Head of Investor Relations Tejas Savant on March 3, 2026, 11:10–11:40 a.m. EST in Boston.
A live audio webcast and replay will be available on Agilent’s Investor Relations website. Agilent reported $6.95 billion revenue for fiscal 2025 and employs approximately 18,000 people worldwide.
Agilent (NYSE: A) announced a quarterly cash dividend of 25.5 cents per share, payable April 22, 2026, to shareholders of record at the close of business March 31, 2026. The company said future dividend timing and amounts remain subject to board determination.
Financials: Agilent reported $6.95 billion revenue in fiscal 2025 and employs approximately 18,000 people worldwide.
Agilent (NYSE: A) awarded Boehringer Ingelheim the inaugural 2025 Instrument Trade‑In Impact Award for leading Agilent partners in sustainable trade‑in activity. In 2025 Boehringer Ingelheim diverted 6,600 kg of instrument waste from landfill via reuse, refurbishment, or proper recycling.
The award recognizes measurable progress toward a circular economy and supports Agilent’s programs to reduce laboratory waste and extend instrument lifecycles.
Agilent (NYSE: A) announced FDA approval of PD-L1 IHC 22C3 pharmDx, Code SK006 as the only FDA‑approved companion diagnostic to identify first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC) patients whose tumors express PD‑L1 and may be eligible for KEYTRUDA.
This marks the seventh FDA companion diagnostic indication for the test and enables PD‑L1 assessment at diagnosis to support first‑line treatment decisions; Agilent reported $6.95 billion revenue in fiscal 2025.